Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?

These are two of healthcare's biggest darlings right now, but one looks better positioned for the long run.Glucagon-like peptide-1 (GLP-1) agonists have taken the healthcare world by storm, emerging as mainstream treatments for patients with diabetes or obesity. Some of these medications include Novo Nordisk's (NVO -1.65%) Ozempic, Wegovy, Rybelsus, and Saxenda, and Eli Lilly's (LLY -1.74%) Mounjaro and Zepbound.Below, I'll dig into which pharmaceutical stock I think is the better buy for the long run. Whil ...